Allurion Technologies, Inc. (ALUR)
Healthcare › Surgical & Medical Instruments & Apparatus
Price History
Feb 9, 2026 — Apr 4, 2026Investment Snapshot
- Piotroski F-Score 1/9 — signs of financial weakness
- ROE of 52.8% — good return on equity
- Revenue declining 53% annually
Allurion Technologies, Inc. (ALUR) is a Healthcare company operating in Surgical & Medical Instruments & Apparatus, listed on the NYSE , with a market capitalisation of $10 million . Key value metrics: Piotroski F-Score 1 out of 9 .
Value Score
Key Metrics
Current vs 5-Year Average
Based on 3 years of SEC filingsRevenue & Net Income
Financial Statements
| Metric | FY22 | FY23 | FY24 |
|---|---|---|---|
| Revenue | $X.XB | $X.XB | $X.XB |
| Gross Profit | $X.XB | $X.XB | $X.XB |
| Operating Income | $X.XB | $X.XB | $X.XB |
| Net Income | $X.XB | $X.XB | $X.XB |
| EBITDA | $X.XB | $X.XB | $X.XB |
| Total Assets | $X.XB | $X.XB | $X.XB |
| Total Liabilities | $X.XB | $X.XB | $X.XB |
Allurion Technologies, Inc. — Fundamental Analysis Summary
On financial health, ALUR shows a weak Piotroski F-Score of 1/9, a signal of deteriorating financial health, and strong return on equity of 52.8% (sector average: -19.8%).
StockPik's composite Value Score for ALUR is 50/100 — an above-average value rating. The score is built from ten fundamental signals: P/E, P/B, PEG ratio, P/S ratio, return on equity, gross margin, debt-to-equity, current ratio, dividend yield, and Piotroski F-Score.
ALUR reports a high gross margin of 65.2% (sector average: 33.5%) and a negative operating margin of -213.2%.
ALUR shows revenue declining at 53% year-over-year, with earnings declining at 10%.